References
- Mowry JB, Spyker DA, Cantilena LR Jr, Bailey JE, Ford M. 2012 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 30th Annual Report. Clin Toxicol (Phila) 2013; 51:949–1229.
- American Association of Poison Control Centers, National Poison Data System, Table 22, Fentanyl Patches and Fentanyl Patch Ingestions, 2012 Data, report run 6/23/2014.
- Firestone M, Goldman B, Fischer B. Fentanyl use among street drug users in Toronto, Canada: behavioural dynamics and public health implications. Int J Drug Policy 2009; 20:90–92.
- Chapman E, Leipsic J, Satkunam N, Churg A. Pulmonary alveolar proteinosis as a reaction to fentanyl patch smoke. Chest 2012; 141:1321–1323.
- Reid BO, Skogvoll E. Pitfalls with the “chest compression-only” approach: the challenge of an unusual cause. Scand J Trauma Resusc Emerg Med 2010;18:45.
- Prosser JM, Jones BE, Nelson L. Complications of oral exposure to fentanyl transdermal delivery system patches. J Med Toxicol 2010;6:443–447.
- Mrvos R, Feuchter AC, Katz KD, Duback-Morris LF, Brooks DE, Krenzelok EP. Whole fentanyl patch ingestion: a multi-center case series. J Emerg Med 2012; 42:549–552.
- Product Information: Fentanyl Transdermal System. Mylan Pharmaceuticals Inc. Morgantown, WV, 2012.
- Roy SD, Flynn GL. Solubility behavior of narcotic analgesics in aqueous media: solubilities and dissociation constants of morphine, fentanyl, and sufentanil. Pharm Res 1989; 6:147–151.
- Product Information: Fentanyl Transdermal System. Watson Pharma, Inc. Parsippany, NJ, 2012.